Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Mucosal Healing Research Advances of Inflammatory Bowel Disease

View through CrossRef
Inflammatory bowel disease (IBD) refers to a group of chronic intestinal diseases, including Crohn's disease (CD) and ulcerative colitis (UC). These diseases cause chronic inflammation of the intestinal mucosa and wall, leading to symptoms such as diarrhea, abdominal pain, constipation, fatigue, etc. Intestinal mucosal barrier can prevent microbial and other antigens enter the intestinal wall, maintain its healthy function. However, Immune system dysregulation, dysbiosis of the gut microbiome, and dysfunction of the intestinal epithelial barrier are key pathogenic mechanisms of IBD. The treatment of IBD remains an important medical challenge, the current treatment mainly by inhibiting immune activity, blocking certain inflammatory molecules. Although these methods can induce mucosal healing (MH), but infection and tumor adverse reactions associated with immunosuppression still need to solve. Therefore, researchers are exploring new treatments, to promote the healing of the intestinal mucosa and maintain intestinal health. This review summarizes the traditional treatment of IBD and the application of new technologies such as hydrogels, organoids, probiotics and prebiotics, which aim to safely and effectively promote mucosal barrier healing and restore intestinal function and balance.
Title: Mucosal Healing Research Advances of Inflammatory Bowel Disease
Description:
Inflammatory bowel disease (IBD) refers to a group of chronic intestinal diseases, including Crohn's disease (CD) and ulcerative colitis (UC).
These diseases cause chronic inflammation of the intestinal mucosa and wall, leading to symptoms such as diarrhea, abdominal pain, constipation, fatigue, etc.
Intestinal mucosal barrier can prevent microbial and other antigens enter the intestinal wall, maintain its healthy function.
However, Immune system dysregulation, dysbiosis of the gut microbiome, and dysfunction of the intestinal epithelial barrier are key pathogenic mechanisms of IBD.
The treatment of IBD remains an important medical challenge, the current treatment mainly by inhibiting immune activity, blocking certain inflammatory molecules.
Although these methods can induce mucosal healing (MH), but infection and tumor adverse reactions associated with immunosuppression still need to solve.
Therefore, researchers are exploring new treatments, to promote the healing of the intestinal mucosa and maintain intestinal health.
This review summarizes the traditional treatment of IBD and the application of new technologies such as hydrogels, organoids, probiotics and prebiotics, which aim to safely and effectively promote mucosal barrier healing and restore intestinal function and balance.

Related Results

Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
Cardiac functions and aortic elasticity in children with inflammatory bowel disease: effect of age at disease onset
AbstractAim:Childhood onset inflammatory bowel disease is more aggressive and has rapidly progressive clinical course than adult inflammatory bowel disease. Early-onset inflammator...
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Pediatric Pilonidal Sinus Disease: A Single-Center Cohort Study of Clinical and Surgical Outcomes
Abstract Introduction: Pilonidal sinus disease is increasingly recognized in the pediatric population, yet evidence on its clinical characteristics and surgical outcomes in childre...
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Risk factor analysis of enterocutaneous fistula after small bowel surgery
Abstract: Background: ECF most frequently follows a complication of abdominal surgery, although a smaller number occur spontaneously in association with conditia Background: Entero...
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inf...

Back to Top